
Wednesday, August 5 | Aegis Vopak, Allcargo Logistics, Aster DM, Aurobindo Pharma, Automotive Axles, Bayer Crop, Berger Paints, Bikaji, Biocon, Bodal Chemicals, Brigade Hotel, Cummins India, Datamatics, eClerx, FDC, Gateway Distriparks, GMM Pfaudler, GNFC, Godrej Agrovet, GE Vernova T&D, JK Lakshmi Cement, JTL Industries, Monte Carlo, Navin Fluorine, Neuland Laboratories, Pace Digitek, Paisalo Digital, Pearl Global, PB Fintech, Power Grid, Shree Renuka Sugar, Rolex Rings, Shilpa Medicare, Snowman Logistics, and Whirlpool of India.
Summary
Pertuzumab has becomes Biocon’s fifth oncology biosimilar approval in both, Europe and the United States, strengthening the company’s global oncology portfolio.
Biocon Ltd. on Wednesday, November 18, said the European Commission (EC) has granted market authorization for Pebrilzo, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union.
Biocon said its pertuzumab biosimilar is the first biosimilar to get the EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach.
According to the company, the pertuzumab biosimilar is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
“With this approval, pertuzumab becomes our fifth oncology biosimilar approval in both, Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high quality, affordable biologic therapies for patients with EHR2-positive breast cancer,” Biocon CEO and managing director Shreehas Tambe said.
Biocon reported its second quarter earnings earlier this month. Its net profit of ₹56.7 crore declined 57.4% from the previous year’s ₹133 crore. It was also below the CNBC-TV18 poll of ₹154.5 crore.
Revenue was up 2.2% at ₹4,389 crore from ₹4,296 crore in the September quarter last year but was below estimates of ₹4,551 crore.
Earnings before interest, taxes, depreciation and amortization (EBITDA) declined marginally by 0.5% to ₹831 crore from ₹835.4 crore last year but was lower than expectations of ₹907.5 crore. EBITDA margin contracted to 18.9% from 19.4% in the year-ago period and from the poll of 19.9% as well.
Shares of Biocon were down 0.3% at ₹358.45 apiece in early trade on Wednesday. The stock has gained 5% in the past month but has declined 16.3% in the last six months and is down 7.9% this year, so far.
Also Read: This midcap IT stock remains CLSA’s ‘high-conviction’ bet among its peers; Check return potential
Biocon gets European Commission’s market authorisation for biosimilar for breast cancer treatment
